The in vitro and in vivo binding of a monoclonal antibody (MAB) that recognizes a tumor-associated carbohydrate antigen was studied in dogs. Monoclonal antibody 155H.7 was raised in response to inoculation of mice with beta-galactose(1-3)betaN-acetylgalactosamine conjugated to human serum albumin. Avidin-biotin-complex immunohistochemical staining of cryostat sections of normal and neoplastic canine tissue specimens revealed heterogenous binding of MAB 155H.7 to the cells of many canine mammary and lung carcinomas and homogenous staining of many sarcomas, including osteogenic sarcoma. In addition, there was variable staining of a variety of normal tissues including some ductual epithelium, peripheral nerve fibers, and some endothelial cells and fibroblasts. Immunoscintigraphy with 131I-labeled MAB 155H.7 was used to study the in vitro distribution of the antibody. The 131I-labeled MAB 155.H.7 was administered to 1 clinically normal dog, 7 dogs with osteogenic sarcoma, 1 dog with undifferentiated sarcoma, and 2 dogs with mammary tumor. Scintigraphy revealed concentration of radioactivity in 8 of 10 tumor sites within 24 hours after MAB administration. The ratio of 131I in tumor sites to 131I in the surrounding normal tissues, compared with the similar ratio of 99mTc-labeled erythrocytes ranged from 1.1 to 4.3 in tumor vs normal tissue with a mean value of 2, confirming tumor localization of the radiolabeled MAB in excess of that associated with enhanced tumor vascularization.

This study was performed to investigate the toxicity of ochratoxin A (OA) to the chromosomes of K562 tumor cell-line in vitro. Chromosomes of K562 tumor cell-line resulted in pseudotriploidy on the control group. Chromosomes of K562 tumor cell-line treated with OA resulted in heteroploidy compared with the control group. The mean number of chromosomes in the karyotype of the control group (60) were 7 in the A group, 5 in the B group, 20 in the C+X group, 7 in the D group, 9 in the E group, 6 in the F group, and 6 in the G+Y group respectively. Treating with 0.7 micro M OA, the number of chromosomes were increased one in E and F group, two in G+Y group compared with control group. In treated with 1.5 micro M OA, the increasing number of chromosome was one in E and F group. In treated with 3 micro M OA, E and F group was increased one and G+Y group were increased two chromosome in G+Y group was decreased one. K562 tumor cell line treated with OA showed Philadelphia-Chromosome in the long arm of the G group karyotype chromosome. The rate of chromosome aberration in K562 tumor cell-line treated with OA was 77 % in 0.7 micro M OA group, 71 % in 1.5 micro M OA group, 82 % in 3 micro M OA group and 94 % in 6 micro M OA group respectively. The rate of chromosome aberration of K562 tumor cell-line treated with OA was high in the high dose level of OA, and chromosome aberration of K562 tumor cell-line treated with OA showed deletion, minute, dicentric-chromosome and translocation in the long arm of the C-group karyotype. As a result of this study, the toxicity of OA showed deletion, minute, dicentric-chromosome and translocation in the long arm of the C-group karyotype, and then, the toxicity of OA resulted in the damage to RNA and protein synthesis in K562 tumor cell-line, and the C-group karyotype of K562 tumor cell-line was target of the toxicity of OA.

The change of plasma prostaglandin E2 level, natural killer cell activity and tumor cell growth were assayed after transplantation of EL-4 leukemia cells in C57BL/6 mice. Plasma prostaglandin E2 level was increased in EL-4 bearing mice, but indomethacin treated mice group showed low level. The tumor-derived prostaglandin E2 inhibited the post-target binding cytolytic process of natural killer activity. Indomethacin inhibited the growth of prostaglandin secreting EL-4 solid tumor